Madrigal Pharmaceuticals’ Post

EyePoint Pharmaceuticals has initiated its phase 3 LUCIA trial in wet AMD. Read more: https://ow.ly/cima50UmKmG #retinalphysician #wetAMD #nAMD #clinicaltrials #ocularinsert #conexiant

Lipella Pharmaceuticals $LIPO Announces Completion Of First Cohort In Phase 2a Trial Of LP-310 For Oral Lichen Planus, Advancing To Next Dose Group #stockstowatch #stocksinnews #Investors #daytrader https://lnkd.in/eXd-HHtT

Quoin Pharmaceuticals (QNRX) Announces Pricing of $6.8 Million Public Offering. Maxim Group LLC is acting as sole placement agent for the offering. Read the full press release: https://lnkd.in/eChkCFKp Eric Cheng, Robert Solomon, Stephen Polsinelli, Sam Teller

Recce Pharmaceuticals Ltd has achieved a major milestone in its Phase II clinical trial of RECCE® 327, with positive early results fueling optimism for future developments. Read More https://lnkd.in/ggknK2bM #PhaseIITrial, #RECCE®327, #ClinicalResults, #AntimicrobialResistance, #MarketOpportunities

Citius Pharmaceuticals (Nasdaq: CTXR) Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules. Read the press release here: https://lnkd.in/efq-MJKR

CLINUVEL PHARMACEUTICALS LTD CLINUVEL Pharmaceuticals reports promising outcomes in vitiligo treatment with SCENESSE, showcasing notable patient responses. Read More https://lnkd.in/gGHwWbn9 #Vitiligo, #SCENESSE, #ClinicalTrials, #PatientOutcomes, #Repigmentation

$GOVX Lesson to be learned from Corbus $CRBP $4 to $44, after 1:30 'death knell' reverse split. GeoVax Labs, Inc. Corbus Pharmaceuticals https://lnkd.in/e3aed7mm

🎥 In this Special Report episode, the panelists provided clinical insight on the utilization of IPX203, its potential benefits and clinical implications, as well as the practicalities of transitioning patients from other therapies. #ParkinsonDisease Amneal Pharmaceuticals 📺 Watch Now: https://lnkd.in/edbzq7-S

Read the full article at https://lnkd.in/gsg5p5iP to catch the latest news on NT-501 for MacTel! Neurotech Pharmaceuticals, Inc.’s latest breakthrough first-in-class MacTel treatment has stumbled unexpectedly, with the FDA pushing back their PDUFA date to March from December. What does that mean for the company, MacTel patients, and the future of retinal care? Dive into the full story for all the details! #Neurotech #MacTel #FDA #MediaMICE

Beximco Pharmaceuticals' FY23-24 Q3: Profits Surge by 51%! A robust performance fueled by soaring sales and savvy cost management. Profit jumps to Tk 136 crore, up from Tk 90 crore last year. Earnings per share (EPS) rise to Tk 3.06. Sales climb by 15% to Tk 1,098 crore. Beximco Pharmaceuticals continues its upward trajectory in the pharmaceutical landscape. #EmergingTiger #BeximcoPharma #ProfitSurge #FY23-24Q3 #BusinessNews